

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 March 2005 (10.03.2005)

PCT

(10) International Publication Number  
**WO 2005/021028 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 38/13**,  
A61P 31/14

Ichijo-heights 203, 232-1 Nishinkuchicho, Nishino-  
toin-nishiiru, Ichijo-dori, Kamigyo-ku, Kyoto 602-0925  
(JP).

(21) International Application Number:  
PCT/EP2004/009804

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellec-  
tual Property, CH-4002 Basel (CH).

(22) International Filing Date:  
2 September 2004 (02.09.2004)

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0320638.0 3 September 2003 (03.09.2003) GB

(71) Applicant (*for all designated States except AT, US*): **NO-  
VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel  
(CH).

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH**  
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HLIKATA, Makoto**  
[JP/JP]; Fujinomori Godoshukusha 217, Kan-yuchi, Ike-  
nouchicho, Fukakusa, Fushimi-ku, Kyoto 612-0031  
(JP). **SHIMOTOHNO, Kunitada** [JP/JP]; Fushimi  
Godosyukusya 245, Nishibugyo-cho, Fushimi-ku,  
Kyoto 612-8104 (JP). **WATASHI, Koichi** [JP/JP];

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

WO 2005/021028 A1

(54) Title: USE OF MODIFIED CYCLOSPORINS FOR THE TREATMENT OF HCV DISORDERS

(57) Abstract: Disclosed are non-immunosuppressive cyclophilin-binding cyclosporins, e.g. of formula (I, Ia or II) as defined herein, having useful properties in the prevention or treatment of Hepatitis C infections.

## USE OF MODIFIED CYCLOSPORINS FOR THE TREATMENT OF HCV DISORDERS

The present invention relates to a new use for non-immunosuppressive cyclosporins.

The cyclosporins comprise a class of structurally distinctive, cyclic, poly-N-methylated undecapeptides, commonly possessing pharmacological, in particular immunosuppressive, or anti-inflammatory activity. The first of the cyclosporins to be isolated was the naturally occurring fungal metabolite Ciclosporin or Cyclosporine, also known as cyclosporin A.

It is well established that cyclosporin A acts by interfering with the process of T cell activation by blocking transcription initiation of IL-2. Cyclosporin A has been shown to form a complex with a 17kD cytosolic protein named as cyclophilin, that occurs in many cell types and has been shown to be identical to peptidyl-prolyl cis-trans isomerase, an enzyme involved in protein folding.

However, it was found that binding to cyclophilin is a necessary but not a sufficient criterion for immunosuppressive activity. The cyclosporin A/cyclophilin complex can also associate with the cellular protein named calcineurin (CN) which belongs to the phosphatase superfamily. This binding abrogates its phosphatase activity, resulting in silencing of transcription factor NF-AT. The inhibition of the CN/NF-AT pathway is the essential mechanism for cyclosporin A mediated immunosuppression.

Cyclosporins which bind strongly to cyclophilin but are not immunosuppressive have been identified. A cyclosporin is considered to be non-immunosuppressive when it has an activity in the Mixed Lymphocyte Reaction (MLR) of no more than 5%, preferably no more than 2%, that of cyclosporin A. The Mixed Lymphocyte Reaction is described by T. Meo in "Immunological Methods", L. Lefkovits and B. Peris, Eds., Academic Press, N.Y. pp. 227 – 239 (1979). Spleen cells ( $0.5 \times 10^8$ ) from Balb/c mice (female, 8 – 10 weeks) are co-incubated for 5 days with  $0.5 \times 10^6$  irradiated (2000 rads) or mitomycin C treated spleen cells from CBA mice (female, 8 – 10 weeks). The irradiated allogeneic cells induce a proliferative response in the Balb c spleen cells which can be measured by labeled precursor incorporation into the DNA. Since the stimulator cells are irradiated (or mitomycin C treated) they do not respond to the Balb/c cells with proliferation but do retain their antigenicity. The  $IC_{50}$  found for the test compound in the MLR is compared with that found for cyclosporin A in a parallel experiment. In addition, non-immunosuppressive cyclosporins lack the capacity of inhibiting CN and the downstream NF-AT pathway.

EP 0 484 281 A1 discloses the use of non-immunosuppressive cyclosporins in the treatment of AIDS or AIDS-related disorders.

It has now surprisingly been found that non-immunosuppressive cyclosporins which bind to cyclophilin have an inhibitory effect on Hepatitis C virus (HCV).


Persistent infection by HCV, which has been identified as the major causative agent of non-A, non-B hepatitis has been considered closely related to liver diseases such as chronic hepatitis, liver cirrhosis or hepatocellular carcinoma. The development of these liver diseases is a major public health problem. Effective anti-HCV therapy is restricted to therapy with interferon or a combination of interferon and ribavirin. However, since the virus is not eliminated from about a half of the HCV patients treated with these known agents, there is still a strong need for alternative anti-HCV agents.

Accordingly, the present invention provides the use of a non-immunosuppressive cyclophilin-binding cyclosporin in the prevention or treatment of Hepatitis C infections or HCV induced disorders.

Hepatitis C infections or HCV induced disorders are e.g. chronic hepatitis, liver cirrhosis or liver cancer, e.g. hepatocellular carcinoma. The non-immunosuppressive cyclophilin-binding cyclosporins may also be used for example as a prophylactic treatment of neonates born to HCV infected mothers or of healthcare workers exposed to the virus, or of transplant recipients, e.g. organ or tissue transplant recipients, e.g. liver transplant, to eliminate possible recurrent HCV infection after transplantation.

A cyclosporin is considered as binding to cyclophilin if it binds to human recombinant cyclophilin at least one fifth as well as does cyclosporin A in the competitive ELISA test described by Quesniaux in Eur. J. Immunol. 1987 17 1359 – 1365. In this test, the cyclosporin to be tested is added during the incubation of cyclophilin with coated BSA-cyclosporin A and the concentration required to give a 50% inhibition of the control reaction without competitor is calculated ( $IC_{50}$ ). The results are expressed as the Binding Ratio (BR), which is the log to the base 10 of the ratio of the  $IC_{50}$  of the test compound and the  $IC_{50}$  in a simultaneous test of cyclosporin A itself. Thus a BR of 1.0 indicates that the test compound binds human cyclophilin one factor of ten less well than does cyclosporin A, and a negative value indicates binding stronger than that of cyclosporin A. The cyclosporins active against HCV have a BR lower than 0.7, preferably equal to or lower than zero.

Examples of non immunosuppressive cyclophilin-binding cyclosporins include e.g. compounds of Formula I



I

wherein

W is MeBmt, dihydro-MeBmt, 8'-hydroxy-MeBmt or O-acetyl-MeBmt<sup>1</sup>;

X is  $\alpha$ Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);

R is Pro, Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl);

Y is MeLeu, thioMeLeu,  $\gamma$ -hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Mealle or MeaThr; N-ethylVal, N-ethylIle, N-ethylThr, N-ethylPhe, N-ethylTyr or N-ethylThr(Oacetyl)

Z is Val, Leu, MeVal or MeLeu,


Q is MeLeu,  $\gamma$ -hydroxy-MeLeu, MeAla or Pro,

T<sub>1</sub> is (D)Ala or Lys,

T<sub>2</sub> is MeLeu or  $\gamma$ -hydroxy-MeLeu, and

T<sub>3</sub> is MeLeu or MeAla.

Preferred compounds of formula I are e.g. compounds of formula Ia



Ia

in which W' is MeBmt, dihydro-MeBmt or 8'-hydroxy-MeBmt;

X is  $\alpha$ Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);

R' is Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl);

Y' is MeLeu,  $\gamma$ -hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Mealle or MeaThr; N-ethylVal, N-ethylIle, N-ethylThr, N-ethylPhe, N-ethylTyr or N-ethylThr(Oacetyl)

Z is Val, Leu, MeVal or MeLeu; and

Q' is MeLeu,  $\gamma$ -hydroxy-MeLeu or MeAla.

The groups W', X, Y', Z, Q' and R' have, independently, the following preferred significances:

- 4 -

W' is preferably W'' where W'' is MeBmt or dihydro-MeBmt;

X is preferably X' where X' is  $\alpha$ Abu or Nva, more preferably X'' where X'' is  $\alpha$ Abu;

R' is preferably R'' where R'' is Sar;

Y' is preferably Y'' where Y'' is  $\gamma$ -hydroxy-MeLeu, MeVal, MeThr, Melle, N-ethylle

or N-ethylVal;

Z is preferably Z' where Z' is Val or MeVal; and

Q' is preferably Q'' where Q'' is MeLeu;

A preferred group of Compounds of formula Ia are those in which W' is W'', X is X', Y' is Y'', Z is Z', Q' is Q'' and R' is R''.


Examples of preferred compounds of Formula Ia are e.g.:

- a) [dihydro-MeBmt]<sup>1</sup>-[ $\gamma$ -hydroxy-MeLeu]<sup>4</sup>-Ciclosporin; BR\* = 0.1; IR<1%
- b) [MeVal]<sup>4</sup>-Ciclosporin; BR = 0.1; IR<1%
- c) [Melle]<sup>4</sup>-Ciclosporin; BR = -0.2; IR <1%
- d) [MeThr]<sup>4</sup>-Ciclosporin;
- e) [ $\gamma$ -hydroxy-MeLeu]<sup>4</sup>-Ciclosporin; BR = 0.4; IR<1%
- f) [Ethyl-Ile]<sup>4</sup>-Ciclosporin; BR = 0.1; IR <2%
- g) [Ethyl-Val]<sup>4</sup>-Ciclosporin; BR = 0; IR <2%
- h) [Nva]<sup>2</sup>-[ $\gamma$ -hydroxy-MeLeu]<sup>4</sup>-Ciclosporin;
- i) [ $\gamma$ -hydroxy-MeLeu]<sup>4</sup>-[ $\gamma$ -hydroxy-MeLeu]<sup>6</sup>-Ciclosporin;
- j) [MeVal]<sup>5</sup>-Ciclosporin; BR = 0.4; IR = 5.3%
- k) [MeOThr]<sup>2</sup>-[(D)MeAla]<sup>3</sup>-[MeVal]<sup>6</sup>-Ciclosporin;
- j) [8'-hydroxy-MeBmt]<sup>1</sup>-Ciclosporin; BR = 0.35; IR= 1.8%
- k) [MeAla]<sup>6</sup>-Ciclosporin; BR = -0.4; IR = 3.2
- l) [ $\gamma$ -hydroxy-MeLeu]<sup>9</sup>-Ciclosporin; BR = 0.15; IR = 2.9

IR = Immunosuppressive Ratio, expressed as a percentage of the activity relative to Cyclosporin A.


Further examples of non-immunosuppressive cyclosporins are the compounds disclosed in WO 98/28330, WO 98/28329 and WO 98/28328, the contents thereof being incorporated herein by reference, e.g. compounds of formula II

- 5 -



wherein

$W_a$  is



wherein  $R_a$  is a residue of formula Ic or Id




in which  $R_4$  is  $C_{1-4}$ alkylthio, amino $C_{1-4}$ alkylthio,  $C_{1-4}$ alkylamino $C_{1-4}$ alkylthio, di $C_{1-4}$ alkylamino- $C_{1-4}$ alkylthio, pyrimidinylthio, thiazolylthio, N-  $C_{1-4}$ alkylimidazolylthio, hydroxy $C_{1-4}$ alkylphenylthio, hydroxy $C_{1-4}$ alkylphenoxy, nitrophenylamino or 2-oxypyrimidin-1-yl, and  $R'_4$  is  $C_{1-4}$ alkyl,

$X_a$  is Abu;

$R_a$  is  $-NMe-CH(R_b)-CO-$  wherein  $R_b$  is H or  $-S-Alk-R_0$  in which Alk- $R_0$  is methyl; or Alk is straight or branched  $C_{2-6}$ alkylene or  $C_{3-6}$ cycloalkylene and  $R_0$  is H; OH; COOH;  $C_{2-5}$ alkoxy-carbonyl;  $NR_1R_2$  in which each of  $R_1$  and  $R_2$ , independently, is selected from H,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{3-6}$ cycloalkyl and phenyl each optionally substituted by halogen,  $C_{1-4}$ alkoxy,  $C_{2-5}$ alkoxycarbonyl, amino,  $C_{1-4}$ alkylamino and/or di $C_{1-4}$ alkyl-amino, and benzyl and a heterocyclic radical, said benzyl and heterocyclic radicals being saturated or unsaturated and containing 5 or 6 ring members and 1 to 3 heteroatoms, or  $R_1$  and  $R_2$  form, together with the nitrogen atom to which they are attached, a 4- to 6 membered heterocycle which may contain another heteroatom chosen from nitrogen, oxygen and sulphur, and which is optionally substituted by  $C_{1-4}$ alkyl, phenyl or benzyl; or each of  $R_1$  and  $R_2$ , independently, is a radical of formula Ib

(Ib)



in which R<sub>1</sub> and R<sub>2</sub> are as defined above, R<sub>3</sub> is H or C<sub>1-4</sub>alkyl and n is an integer ranging from 2 to 4;

Y<sub>a</sub> is MeLeu or γ-hydroxy-MeLeu;

Z<sub>a</sub> is Val; and

Q<sub>a</sub> is MeLeu,

with the proviso that R<sub>b</sub> is not H when Y<sub>a</sub> is MeLeu,

or a pharmaceutically acceptable salt thereof.

In the formula II, when R<sub>1</sub> and/or R<sub>2</sub> is a heterocyclic residue, it may be pyridyl, tetrahydropyridyl, piperidyl, imidazolyl, oxazolyl or thiazolyl.. When R<sub>1</sub> and R<sub>2</sub> form a heterocyclic residue with the nitrogen atom to which they are attached, by way of example, the heterocyclic residue may be chosen from azetidiny, piperidyl, piperazinyl, N-methylpiperazinyl, N-phenylpiperazinyl, N-benzylpiperazinyl, pyridyl, imidazolyl, morpholino, thiomorpholino, tetrahydropyridyl, methyltetrahydropyridyl (for example 4-methyltetrahydropyridyl) or phenyltetrahydropyridyl (for example 4-phenyltetrahydropyridyl).

The Compounds of formula I, Ia or II may be obtained in a variety of ways, which may be classified as:

- 1) Fermentation
- 2) Biotransformation
- 3) Derivatisation
- 4) Partial Synthesis
- 5) Total Synthesis

as disclosed e.g. in EP 0 484 281 A1, WO 00/01715, WO 98/28330, WO 98/28329 or WO 98/28328 the contents thereof being incorporated herein by reference.

In a series of further specific or alternative embodiments, the present invention also provides:

- 1.1 A method for preventing or treating Hepatitis C infections or HCV induced disorders in a subject in need thereof, comprising administering to said subject a

therapeutically effective amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II.

According to the invention, the non-immunosuppressive cyclophilin-binding cyclosporine may be administered in an amount effective to alleviate or eliminate one or more of the signs or symptoms of hepatitis C, for example, effective to lower the HCV-RNA measured in a serum sample of a subject.

- 1.2 A method for inhibiting HCV replication in a medium, comprising applying to this medium an effective amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II.
- 1.3 A method for inhibiting HCV replication in a patient in need thereof, comprising administering to this subject a therapeutically effective amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II.
- 1.4 A method for preventing the recurrence of HCV infection in a transplant recipient in need thereof, comprising administering to said recipient a therapeutically effective amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II.
2. Use of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II, in the preparation of a pharmaceutical composition for use in any method as defined above.
3. A pharmaceutical composition for use in any method as defined above, comprising a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II, together with one or more pharmaceutically acceptable diluents or carriers therefor.

Utility of the non-immunosuppressive cyclophilin-binding cyclosporins (hereinafter "cyclosporins of the invention") in treating diseases and conditions as hereinabove specified may be demonstrated in standard animal or clinical tests, e.g. in accordance with the methods described hereinafter.

#### A. In vitro

Cell culture: Huh-7 and MH-14 cells, HCV replicon cells, are cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (FBS). PH5CH8 cells are cultured in a 1:1 mixture of DMEM and F12 medium supplemented with 100 ng/ml of epidermal growth factor, 10 µ/ml of insulin, 0.36 µg/ml of hydrocortisone, 5 µg/ml of transferrin, 5µg/ml of



linoleic acid, 20 ng/ml of selenium, 4 µg/ml of glucagon, 10 ng/ml of prolactin, 10 µg/ml of gentamicin, 200 µg/ml of kanamycin, and 2 % FBS.

Immunoblot analysis: Immunoblot analysis is performed as described by K. Watashi et al., Virology 2001, 286, 391 – 402. The primary antibodies used in this experiment are anti-NS5A, anti-NS5B, and anti-β-actin (Sigma) antibodies.

Indirect immunofluorescence analysis: Indirect immunofluorescence analysis is performed as described by K. Watashi, supra. The primary antibodies used in this experiment are anti-NS5A and anti-PDI (StressGen) antibodies.

Reverse transcription (RT)-polymerase chain reaction (PCR) analysis

Total RNA of cultured cells is isolated with Sepasol-RNA I Super (nacalai tesque) as recommended by the manufacturer. RT-PCR analysis is performed using a one step RNA PCR kit (Takara) according to the manufacturer's directions. The primers used for detection of mRNAs for 2', 5'-oligoadenylate synthetase and double strand RNA-dependent protein kinase are 5'-CCGTGAAGTTTGAGGTCCAG-3', 5'-GACTAATTCCAAGACCGTCCG-3' and 5'-TGGCCGCTAAACTTGCATATC-3', 5'-GCGAGTGTGCTGGTCACTAAAG-3', respectively.

Northern blot analysis: Northern blot analysis is performed as described by H. Kishine et al., Biochem. Biophys. Res. Commun., 2002, 47, 119 – 125. The probe complementary to the NS5B sequence used in this experiment is described by H. Kishine, supra.

Real time RT-PCR analysis: The 5'-UTR of HCV genome RNA is quantified using the ABI PRISM 7700 sequence detector (AppliedBiosystems) as described by T. Takeuchi et al., Gastroenterology, 1999, 116, 636 – 642. The forward and reverse primers used in this experiment are 5'-CGGGAGAGCCATAGTGG-3' and 5'-AGTACCACAAGGCCTTTCG-3', respectively. The fluorogenic probe is 5'-CTGCGGAACCGGTGAGTACAC-3'. As an internal control, ribosomal RNA is also quantified using TaqMan Ribosomal RNA Control Reagents (Applied Biosystems).

In vitro HCV infection experiment: The In vitro HCV infection experiment is performed essentially as described by N. Kato et al., Jpn. J. Cancer Res. 1996, 87, 787 – 792 and M. Ikada et al., Virus Res., 1998, 56, 157 – 167. PH5CH8 cells ( $1 \times 10^5$ ) are infected with the plasma 1B-2 (equivalent to  $10^4$  to  $10^5$  HCV RNA copies), which is prepared from an HCV-positive blood donor. At 24 h post-inoculation, the cells are washed three times with phosphate-buffered saline (PBS) and maintained with fresh medium.

Transfection and reporter assay: Transfection into MH-14 and H9 cells is performed using FuGENE 6 (Roche) and Lipofectamine 2000 transfection reagent (Invitrogen), respectively, according to the manufacturer's protocol. The reporter assay is performed as described by K. Watashi, supra. The reporter plasmids used in this study are pNFAT-Luc, pAP1-Luc, pNFkB-Luc (PathDetect Reporter System; Stratagene), and pRL-TK (Dual-luciferase reporter assay system; Promega).

The effect of various cyclosporins of the invention on the replication of the HCV genome using MH-14 cells, in which the HCV subgenomic replicon as shown in Fig. 1A is autonomously replicated. Treatment with a cyclosporin of the invention, e.g. [Melle]<sup>4</sup>-ciclosporin, e.g. at 1 µg/ml, as well as 100 U/ml IFNα which is used as a positive control for 7 days decreases the amount of HCV NS5A and NS5B proteins to levels undetectable by immunoblot analysis. Indirect immunofluorescence analysis showed that NS5A protein production is reduced in all the cells treated with 1 µg/ml cyclosporin of the invention, while the level of protein disulfide isomerase (PDI), which is an endoplasmic reticulum marker, as an internal control is not altered under this condition. The cyclosporins of the invention decrease in this assay HCV protein expression in HCV replicon cells.

Replicon RNA is analyzed in MH-14 cells treated with or without a cyclosporin of the invention or IFNα for 7 days by northern blot analysis. Treatment with e.g. 1 µg/ml cyclosporin of the invention, e.g. [Melle]<sup>4</sup>-ciclosporin, decreases the amount of replicon RNA to an undetectable level. Treatment with 100U/ml IFNα produces a similar effect. In addition the titer is gradually decreased and the level of HCV RNA is reduced to about 1/400 of the original on the 7<sup>th</sup> day. In the case of a co-treatment with IFNα, a further reduction at any time point examined (3<sup>th</sup>, 5<sup>th</sup> and 7<sup>th</sup> day) compared with the single treatment with either the cyclosporin or IFNα: the replicon RNA level in MH-14 cells treated with both the cyclosporin and IFNα for 7 days is significantly decreased over that in the cells treated with IFNα alone.

Furthermore, PH5CH8 cells (non-neoplastic hepatocyte cell line) are treated with HCV-positive plasma and subsequently the HCV RNA genome titer at various time-points post-inoculation is quantified by real time RT-PCR analysis. While the HCV RNA genome titer on the 5<sup>th</sup> day post-inoculation in the cells is increased about 10-fold compared with that on the 1<sup>st</sup> day, a significant increase of the HCV RNA genome titer at these time points was not observed in the cells treated continuously with a cyclosporin of the invention, e.g. [Melle]<sup>4</sup>-ciclosporin, or IFNα. The cyclosporins of the invention inhibit the replication of HCV infected cultured hepatocytes.

Results are shown in Fig. 2E, 2F and 2G: immunoblot analysis (2E), indirect immunofluorescence analysis (2F) and real time RT-PCR analysis (2G) is performed using MH-14 cells treated with [Melle]<sup>4</sup>-Ciclosporin (■) or an non cyclophilin binding cyclosporin (●), e.g. 6-[[R-(E)]-6,7-Didehydro-N,4-dimethyl-3-oxo-L-2-aminooctanoic acid]-7-L-valine-cyclosporin A. Control in 2E and 2F (1<sup>st</sup> row), no treatment; CysA in 2E, 1 µg/ml ; [Melle]<sup>4</sup>-Ciclosporin in 2E (■) and 2F (■), 1µg/ml; the non cyclophilin binding cyclosporin in 2E (●) and 2F (●), 1µg/ml.

#### B. Clinical Trial

A total of 15 patients with chronic Hepatitis C infection are enrolled in a study of 2 weeks. Each patient receives a cyclosporine of the invention, e.g. [Melle]<sup>4</sup>-ciclosporin, at a dose of 7 to 15 mg/kg p.o. The serum levels of Hepatitis C antigens are determined at day 0 and day 14 in each patient.

A person suffering from hepatitis C infection, in particular chronic HCV infection, may exhibit one or more of the following signs or symptoms: (a) elevated ALT, (b) positive test for anti-HCV antibodies, (c) presence of HCV as demonstrated by a positive test for HCV-RNA, (d) clinical stigmata of chronic liver disease, (e) hepatocellular damage. Such criteria may not only be used to diagnose Hepatitis C, but can be used to evaluate a patient's response to drug treatment.

Elevated serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are known to occur in uncontrolled Hepatitis C, and a complete response to treatment is generally defined as the normalization of these serum enzymes, particularly ALT (Davis et al., 1989, New Eng. J. Med. 321:1501-1506). ALT is an enzyme released when liver cells are destroyed and is symptomatic of HCV infection.

In order to follow the course of HCV replication in subjects in response to drug treatment, HCV RNA may be measured in serum samples by, for example, a nested polymerase chain reaction assay that uses two sets of primers derived from the N53 and N54 non-structural gene regions of the HCV genome. Farci et al., 1991, New Eng. J. Med. 325:98-104. Ulrich et al., 1990, J. Clin. Invest., 86:1609-1614.

Histological examination of liver biopsy samples may be used as a second criteria for evaluation. See, e.g., Knodell et al., 1981, Hepatology 1:431-435, whose Histological Activity

Index (portal inflammation, piecemeal or bridging necrosis, lobular injury and fibrosis) provides a scoring method for disease activity.

Daily dosages required in practicing the method of the present invention will vary depending upon, for example, the non-immunosuppressive cyclophilin-binding cyclosporin employed, the host, the mode of administration, the severity of the condition to be treated. A preferred daily dosage range is about from 1 to 50 mg/kg per day as a single dose or in divided doses. Suitable daily dosages for patients are on the order of from e.g. 1 to 20 mg/kg p.o. or i.v. Suitable unit dosage forms for oral administration comprise from ca. 0.25 to 10 mg/kg active ingredient, e.g. [Melle]<sup>4</sup>-cyclosporin, together with one or more pharmaceutically acceptable diluents or carriers therefor.

The cyclosporins of the invention may be administered by any conventional route, in particular enterally, e.g. orally, for example in the form of solutions for drinking, tablets or capsules or parenterally, for example in the form of injectable solutions or suspensions. Preferred pharmaceutical compositions may be e.g. those based on microemulsions as described in UK 2,222,770 A.

The cyclosporins of the invention may be administered as the sole ingredient or together with other drugs, e.g. a drug which has anti-HCV activities, e.g. an interferon, e.g. interferon- $\alpha$ -2a or interferon- $\alpha$ -2b, e.g. Intron<sup>R</sup> A, Roferon<sup>R</sup>, Avonex<sup>R</sup>, Rebif<sup>R</sup> or Betaferon<sup>R</sup>, or an interferon conjugated to a water soluble polymer or to human albumin, e.g. albuferon, an anti-viral agent, e.g. ribavirin, lamivudine, NV08 or NM283, an inhibitor of the HCV encoded factors like the NS3/4A protease, the helicase or RNA polymerase or a prodrug of such an inhibitor, an anti-fibrotic agent, e.g. a N-phenyl-2-pyrimidine-amine derivative, e.g. imatinib, an immune modulating agent, e.g. mycophenolic acid, a salt or a prodrug thereof, e.g. sodium mycophenolate or mycophenolate mofetil, or a S1P receptor agonist, e.g. FTY720 or an analogue thereof optionally phosphorylated, e.g. as disclosed in EP627406A1, EP778263A1, EP1002792A1, WO02/18395, WO02/76995, WO 02/06268, JP2002316985, WO03/29184, WO03/29205, WO03/62252 and WO03/62248.

Conjugates of interferon to a water-soluble polymer are meant to include especially conjugates to polyalkylene oxide homopolymers such as polyethylene glycol (PEG) or polypropylene glycols, polyoxyethylenated polyols, copolymers thereof and block copolymers thereof. As an alternative to polyalkylene oxide-based polymers, effectively non-antigenic materials such as dextran, polyvinyl pyrrolidones, polyacrylamides, polyvinyl alcohols, carbohydrate-based polymers and the like can be used. Such interferon-polymer conjugates

are described in U.S. Pat. Nos. 4,766,106, 4,917,888, European Patent Application No. 0 236 987, European Patent Application No. 0 510 356 and International Application Publication No. WO 95/13090. Since the polymeric modification sufficiently reduces antigenic responses, the foreign interferon need not be completely autologous. Interferon used to prepare polymer conjugates may be prepared from a mammalian extract, such as human, ruminant or bovine interferon, or recombinantly produced. Preferred are conjugates of interferon to polyethylene glycol, also known as pegylated interferons.

Especially preferred conjugates of interferon are pegylated alfa-interferons, for example pegylated interferon- $\alpha$ -2a, pegylated interferon- $\alpha$ -2b; pegylated consensus interferon or pegylated purified interferon- $\alpha$  product. Pegylated interferon- $\alpha$ -2a is described e.g. in European Patent 593,868 and commercially available e. g. under the tradename PEGASYS<sup>®</sup> (Hoffmann-La Roche). Pegylated interferon- $\alpha$ -2b is described, e.g. in European Patent 975,369 and commercially available e.g. under the tradename PEG-INTRON A<sup>®</sup> (Schering Plough). Pegylated consensus interferon is described in WO 96/11953. The preferred pegylated  $\alpha$ -interferons are pegylated interferon- $\alpha$ -2a and pegylated interferon- $\alpha$ -2b. Also preferred is pegylated consensus interferon.

Daily dosages with respect to the co-agent used will vary depending upon, for example, the compound employed, the host, the mode of administration and the severity of the condition to be treated. For example, lamivudine may be administered at a daily dosage of 100mg. The pegylated interferon may be administered parenterally one to three times per week, preferably once a week, at a total weekly dose ranging from 2 to 10 million IU, more preferable 5 to 10 million IU, most preferable 8 to 10 million IU.

In accordance with the foregoing the present invention provides in a yet further aspect:

4. A pharmaceutical combination comprising a) a first agent which is a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II, and b) a co-agent, e.g. a second drug agent as defined above, e.g. for use in any method as defined above.
5. A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a non-immunosuppressive cyclophilin-binding cyclosporin, e.g. a compound of formula I, Ia or II, and a co-agent, e.g. a second drug agent as defined above.

The terms "co-administration" or "combined administration" or the like as utilized herein are meant to encompass administration of the selected therapeutic agents to a single patient, and are intended to include treatment regimens in which the agents are not necessarily administered by the same route of administration or at the same time.


The administration of a pharmaceutical combination of the invention results in a beneficial effect, e.g. a synergistic therapeutic effect, compared to a monotherapy applying only one of its pharmaceutically active ingredients. A preferred synergistic combination is a combination of a non-immunosuppressive cyclophilin-binding cyclosporin with an interferon, optionally conjugated to a polymer.

A further preferred combination is a combination of a non-immunosuppressive cyclophilin-binding cyclosporin with mycophenolic acid, a salt or a prodrug thereof, or with a S1P receptor agonist, e.g. FTY720.

[Melle]<sup>4</sup>-cyclosporin or [MeVal]<sup>4</sup>-Cyclosporin is a preferred non-immunosuppressive cyclophilin-binding cyclosporin for use according to the invention.

## CLAIMS

1. Use of a cyclosporin in the preparation of a pharmaceutical composition for preventing or treating Hepatitis C infections or HCV induced disorders, wherein the cyclosporin (i) binds to human recombinant cyclophilin with a binding ratio (BR) of less than 0.7, BR being the log to the base 10 of the ratio of the  $IC_{50}$  of the cyclosporin to the  $IC_{50}$  in a simultaneous test of cyclosporin A as measured in a competitive ELISA test; and (ii) has an activity in the Mixed lymphocyte Reaction of not more than 5% that of cyclosporin A.
2. Use of a cyclosporin according to claim 1 in the preparation of a pharmaceutical composition for inhibiting HCV replication.
3. Use of a cyclosporin according to claim 1 in the preparation of a pharmaceutical composition for preventing the recurrence of HCV infection in a transplant recipient.
4. Use according to claim 1, 2 or 3 wherein the cyclosporin is a compound of Formula I



wherein

W is MeBmt, dihydro-MeBmt, 8'-hydroxy-MeBmt or O-acetyl-MeBmt<sup>1</sup>;

X is  $\alpha$ Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);

R is Pro, Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl);

Y is MeLeu, thioMeLeu,  $\gamma$ -hydroxy-MeLeu, Melle, MeVal, MeThr, MeAla, Mealle or MeaThr; N-ethylVal, N-ethylIle, N-ethylThr, N-ethylPhe, N-ethylTyr or N-ethylThr(Oacetyl)

Z is Val, Leu, MeVal or MeLeu,


Q is MeLeu,  $\gamma$ -hydroxy-MeLeu, MeAla or Pro,

T<sub>1</sub> is (D)Ala or Lys,

T<sub>2</sub> is MeLeu or  $\gamma$ -hydroxy-MeLeu, and

T<sub>3</sub> is MeLeu or MeAla;

a compound of Formula Ia



in which W' is MeBmt, dihydro-MeBmt or 8'-hydroxy-MeBmt;

X is  $\alpha$ Abu, Val, Thr, Nva or O-methyl threonine (MeOThr);

R' is Sar, (D)-MeSer, (D)-MeAla, or (D)-MeSer(Oacetyl);


Y' is MeLeu,  $\gamma$ -hydroxy-MeLeu, MeIle, MeVal, MeThr, MeAla,

Mealle or MeaThr; N-ethylVal, N-ethylIle, N-ethylThr, N-ethylPhe, N-ethylTyr  
or N-ethylThr(Oacetyl)

Z is Val, Leu, MeVal or MeLeu; and


Q' is MeLeu,  $\gamma$ -hydroxy-MeLeu or MeAla.

or a compound of formula II



wherein

W<sub>a</sub> is



wherein R<sub>a</sub> is a residue of formula Ic or Id



in which R<sub>4</sub> is C<sub>1-4</sub>alkylthio, aminoC<sub>1-4</sub>alkylthio, C<sub>1-4</sub>alkylaminoC<sub>1-4</sub>alkylthio,

diC<sub>1-4</sub>alkylamino-C<sub>1-4</sub>alkylthio, pyrimidinylthio, thiazolylthio, N- C<sub>1-4</sub>alkylimidazolylthio,


hydroxyC<sub>1-4</sub>alkylphenylthio, hydroxyC<sub>1-4</sub>alkylphenoxy, nitrophenylamino or 2-oxopyrimidin-

1-yl, and R'<sub>4</sub> is C<sub>1-4</sub>alkyl,

X<sub>a</sub> is Abu;



$R_a$  is  $-\text{NMe}-\text{CH}(R_b)-\text{CO}-$  wherein  $R_b$  is H or  $-\text{S}-\text{Alk}-R_0$  in which Alk- $R_0$  is methyl; or Alk is straight or branched  $\text{C}_{2-6}$ alkylene or  $\text{C}_{3-6}$ cycloalkylene and  $R_0$  is H; OH; COOH;  $\text{C}_{2-5}$ alkoxycarbonyl;  $\text{NR}_1\text{R}_2$  in which each of  $R_1$  and  $R_2$ , independently, is selected from H,  $\text{C}_{1-4}$ alkyl,  $\text{C}_{2-4}$ alkenyl,  $\text{C}_{3-6}$ cycloalkyl and phenyl each optionally substituted by halogen,  $\text{C}_{1-4}$ alkoxy,  $\text{C}_{2-5}$ alkoxycarbonyl, amino,  $\text{C}_{1-4}$ alkylamino and/or di $\text{C}_{1-4}$ alkyl-amino, and benzyl and a heterocyclic radical, said benzyl and heterocyclic radicals being saturated or unsaturated and containing 5 or 6 ring members and 1 to 3 heteroatoms, or  $R_1$  and  $R_2$  form, together with the nitrogen atom to which they are attached, a 4- to 6 membered heterocycle which may contain another heteroatom chosen from nitrogen, oxygen and sulphur, and which is optionally substituted by  $\text{C}_{1-4}$ alkyl, phenyl or benzyl; or each of  $R_1$  and  $R_2$ , independently, is a radical of formula Ib



in which  $R_1$  and  $R_2$  are as defined above,  $R_3$  is H or  $\text{C}_{1-4}$ alkyl and  $n$  is an integer ranging from 2 to 4;

$Y_a$  is MeLeu or  $\gamma$ -hydroxy-MeLeu;

$Z_a$  is Val; and

$Q_a$  is MeLeu,

with the proviso that  $R_b$  is not H when  $Y_a$  is MeLeu,

or a pharmaceutically acceptable salt thereof. .

5. A pharmaceutical composition for preventing or treating Hepatitis C infections or HCV induced disorders, comprising a cyclosporin according to claim 1 together with one or more pharmaceutically acceptable diluents or carriers therefor.

6. A pharmaceutical combination comprising a) a first agent which is a cyclosporin according to claim 1, and b) a co-agent having anti-HCV properties.

7. A pharmaceutical combination for use in the prevention or treatment of Hepatitis C infections or HCV induced disorders, comprising a) a first agent which is a cyclosporin according to claim 1, and b) a co-agent selected from an agent having anti-HCV properties, an anti-fibrotic agent, an immune modulating agent or a S1P receptor agonist

8. A method for preventing or treating Hepatitis C infections or HCV induced disorders in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a cyclosporin according to claim 1.
9. A method for inhibiting HCV replication in a medium, comprising applying to this medium an effective amount of a cyclosporin according to claim 1.
10. A method for inhibiting HCV replication in a patient in need thereof, comprising administering to this subject a therapeutically effective amount of a cyclosporin according to claim 1.
11. A method for preventing the recurrence of HCV infection in a transplant recipient in need thereof, comprising administering to said recipient a therapeutically effective amount of a cyclosporin according to claim 1.
12. A method according to any one of claims 8 to 11, comprising co-administration concomitantly or in sequence of a therapeutically effective amount of a cyclosporin as defined in claim 1 and a co-agent selected from an agent having anti-HCV properties, an anti-fibrotic agent, an immune modulating agent or a S1P receptor agonist.

FIGURE 1/2



**A**

FIGURE 2/2



## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP2004/009804

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 7 A61K38/13 A61P31/14

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/62540 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); HIESTAND PETER (CH)) 9 December 1999 (1999-12-09) see abstract and page 1, page 2 last line and pages 10-11	6,7
A	WO 02/32447 A (SHIBASAKI FUTOSHI ; HINO MOTOHIRO (JP); NAKADA HIROHISA (JP); UCHINO H) 25 April 2002 (2002-04-25) cited in the application see page 2 lines 17-30, pages 3-4	1-12
A	EP 0 484 281 A (SANDOZ AG ; SANDOZ LTD (CH); SANDOZ AG (DE)) 6 May 1992 (1992-05-06) cited in the application see claims and paragraphs '0052!-'0054! ----- -/--	1-12



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

26 November 2004

Date of mailing of the international search report

03/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax (+31-70) 340-3018

Authorized officer

Merckling-Ruiz, V

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP2004/009804

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 994 299 A (CARRY JEAN-CHRISTOPHE ET AL) 30 November 1999 (1999-11-30) cited in the application see claims, col.2 lines 3-9 and col.10 -----	6,7
A	US 2002/102279 A1 (CHIBA KENJI ET AL) 1 August 2002 (2002-08-01) see abstract, paragraphs '0037!, '0038! and '0047!, example 3 -----	1-12

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP2004/009804

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —  
because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 5 and 8-12 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/009804

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9962540	A	09-12-1999	AU 750422 B2 18-07-2002
			AU 4372499 A 20-12-1999
			BR 9910860 A 06-03-2001
			CA 2333315 A1 09-12-1999
			CN 1304315 T 18-07-2001
			WO 9962540 A1 09-12-1999
			EP 1082130 A1 14-03-2001
			HU 0102142 A2 28-11-2001
			ID 27576 A 12-04-2001
			JP 2002516873 T 11-06-2002
			NO 20006113 A 25-01-2001
			PL 344451 A1 05-11-2001
			SK 18142000 A3 11-06-2001
			ZA 200006464 A 11-03-2002
WO 0232447	A	25-04-2002	AU 9596601 A 29-04-2002
			CA 2426381 A1 25-04-2002
			EP 1372695 A2 02-01-2004
			WO 0232447 A2 25-04-2002
			JP 2004517818 T 17-06-2004
			US 2004033946 A1 19-02-2004
EP 0484281	A	06-05-1992	AT 148469 T 15-02-1997
			AU 649277 B2 19-05-1994
			AU 8692391 A 07-05-1992
			CA 2054590 A1 03-05-1992
			CS 9103297 A3 13-05-1992
			CY 2159 A 23-08-2002
			DE 69124459 D1 13-03-1997
			DE 69124459 T2 10-07-1997
			DK 484281 T3 17-02-1997
			EP 0484281 A2 06-05-1992
			ES 2095926 T3 01-03-1997
			FI 915135 A 03-05-1992
			GR 3022592 T3 31-05-1997
			GR 3035323 T3 30-04-2001
			HK 1005741 A1 22-01-1999
			HU 62337 A2 28-04-1993
			IE 913824 A1 22-05-1992
			IL 99912 A 12-09-1996
			JP 2740775 B2 15-04-1998
			JP 5208996 A 20-08-1993
			KR 203556 B1 15-06-1999
			MX 9101869 A1 01-04-1993
			NZ 240421 A 28-04-1993
			PL 292248 A1 27-07-1992
			PT 99410 A , B 30-09-1992
			SK 278808 B6 04-03-1998
			US 5981479 A 09-11-1999
			US 6255100 B1 03-07-2001
			US 5767069 A 16-06-1998
			ZA 9108718 A 03-05-1993
			RU 2085589 C1 27-07-1997
US 5994299	A	30-11-1999	FR 2757521 A1 26-06-1998
			AT 218582 T 15-06-2002
			AU 5669398 A 17-07-1998
			DE 69713152 D1 11-07-2002



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP2004/009804

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5994299 . A		DK 951474 T3	16-09-2002
		EP 0951474 A1	27-10-1999
		ES 2178038 T3	16-12-2002
		WO 9828330 A1	02-07-1998
		JP 2001507347 T	05-06-2001
		PT 951474 T	29-11-2002
		ZA 9711607 A	24-06-1998
US 2002102279 A1	01-08-2002	JP 11080026 A	23-03-1999
		US 2004092603 A1	13-05-2004
		US 6004565 A	21-12-1999

This Page Blank (uspto)